2023 World Conference on Lung Cancer (Posters)-P2.08. A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab

P2.08. A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab - PDF(Abstract)

Back to course

Pdf Summary

This document discusses a Phase 2 study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, alone or in combination with Nivolumab for the treatment of metastatic non-small cell lung cancer (NSCLC). Mecbotamab Vedotin is a conditionally active biologic (CAB) anti-AXL antibody-drug conjugate that is being developed as a therapy for advanced solid tumors. AXL is a protein tyrosine kinase expressed in various tumor types, and increased AXL expression has been associated with tumor resistance to chemotherapy and PD-1 inhibitors. <br /><br />The study, named BA3011-002, is an ongoing Phase 2 trial that aims to evaluate the efficacy and safety of BA3011 alone or in combination with Nivolumab in patients with AXL-expressing metastatic NSCLC. To be eligible, patients must have experienced treatment failure with an approved PD-1/L1 treatment, EGFR inhibitor, or ALK inhibitor. Treatment failure is defined as disease progression on the inhibitor or discontinuation due to an adverse event. The trial is open-label and multicenter, with enrollment completion expected in 2023.<br /><br />The rationale for using BA3011-based therapy is that patients who have previously failed EGFR or ALK inhibitors have shown minimal benefit with subsequent PD-1 monotherapy. BA3011, with its conditional and reversible binding properties, aims to reduce off-tumor toxicity, improve pharmacokinetics, and potentially overcome resistance mechanisms associated with AXL upregulation.<br /><br />This study is part of the larger session on Metastatic Non-small Cell Lung Cancer - Immunotherapy at the WCLC 2023 conference. The session aims to explore new immunotherapeutic approaches for the treatment of metastatic NSCLC. The presentation of this study will take place during the session on Monday, September 11, 2023.

Asset Subtitle

Edwin Yau

Meta Tag

Speaker Edwin Yau

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

Mecbotamab Vedotin

BA3011

CAB-AXL-ADC

non-small cell lung cancer

metastatic NSCLC

biologic antibody-drug conjugate

AXL expression

PD-1 inhibitors

Phase 2 trial

immunotherapy